Genetic test may help some breast cancer patients avoid unnecessary chemo
NCT ID NCT03961880
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 270 women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Doctors used a genetic test called OncotypeDX to estimate each patient's risk of the cancer coming back. The goal was to see how the test results influenced whether patients received chemotherapy. The study also checked for cancer cells in the bone marrow to see if there was a link with the genetic risk score.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department for Women's Health
Tübingen, Baden-Wurttemberg, 72086, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early sexual health counseling transform breast cancer recovery?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- What helps or hinders a breast cancer referral? a study listens to Women's stories
- Heating up tumors: could thermal therapy boost immune attack on breast cancer?
- Hypnosis may ease Chemotherapy's toll on breast cancer patients